Stocks To Buy Now

Blog


Nutra Pharma Corp. (NPHC) Engages QualityStocks Corporate Communications Suite

Nutra Pharma Corp., a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.

“We are pleased to have engaged the services of QualityStocks and look forward to a long and fruitful relationship with them as we work to better communicate our progress with shareholders and the general public,” said Nutra Pharma’s chairman and CEO Rik Deitsch. “We believe that Nutra Pharma has an important role to play not only in the traditional ethical arena, but in the less-well-known homeopathic domain as well. We are committed to increasing corporate value through the continued discovery of revolutionary pharmaceutical treatments, expanded distribution reach, and general brand awareness.”

Under the agreement, QualityStocks will strategically use its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to relay Nutra Pharma’s corporate message and progress to the investment community.

“QualityStocks enthusiastically welcomes Nutra Pharma,” said Managing Director Michael McCarthy. “Nutra Pharma is one of those progressive pioneering companies that do more than sell products; their work makes our lives better. It is an honor to have the Nutra Pharma team on board and we look forward to helping the company reach its corporate communication goals.”

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

March 20, 2026

Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its […]

Rotate your device 90° to view site.